What is the current Price Target for the Pluristem Therapeutics Inc. stock?

The average Pluristem Therapeutics Inc. target price is $12.00. This is 179.07% higher than the current stock price. 1 Analyst has issued a Pluristem Therapeutics Inc. price target 2026.

How high will the Pluristem Therapeutics Inc. stock rise?

No reliable answer can be given as to how high the Pluristem Therapeutics Inc. stock will rise. The performance of stocks, including the Pluristem Therapeutics Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Pluristem Therapeutics Inc. stock today?

The performance of Pluristem Therapeutics Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Pluristem Therapeutics Inc. stock fall?

The decline in Pluristem Therapeutics Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Pluristem Therapeutics Inc. Forecast, price target & analysts

$4.30

3.26%

Nasdaq, Thu, Jun 12 2025

ISIN

US72940R1023

Symbol

PSTI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts Strategies

Pluristem Therapeutics Inc. Target price 2025 - Analyst rating & recommendation

Pluristem Therapeutics Inc. Classifications & Recommendation:

Buy

100%

Pluristem Therapeutics Inc. Price Target

Target Price	$12.00
Price	$4.30
Potential	179.07% register free of charge
Number of Estimates	1

	1 Analyst has issued a Pluristem Therapeutics Inc. price target 2026. The average Pluristem Therapeutics Inc. target price is $12.00. This is 179.07% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend Pluristem Therapeutics Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Pluristem Therapeutics Inc. stock has an average upside potential 2026 of 179.07% register free of charge . Most analysts recommend the Pluristem Therapeutics Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Jun '24	2025 Estimates
Revenue Million $	0.33	1.58
	13.79%	379.88%

2 Analysts have issued a sales forecast Pluristem Therapeutics Inc. 2025 . The average Pluristem Therapeutics Inc. sales estimate is

Unlock

. This is

Unlock

than the revenue of the last 12 months(TTM). The highest sales forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics:

2024	$330k	13.79%
2025	$1.6m 379.88% Unlock
2026	$4.5m 186.25% Unlock
2027	$12.2m 169.63% Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Annually

	Jun '24	2025 Estimates
EV/Sales		20.43

Based on analysts' sales estimates for 2025, the Pluristem Therapeutics Inc. stock is valued at an EV/Sales of

Unlock

and an P/S ratio of

Unlock

This results in the following potential growth metrics and future valuations:

Current	31.41	63.57%
2025	20.43 34.96% Unlock
2026	7.14 65.07% Unlock
2027	2.65 62.91% Unlock

Current	32.70	64.43%
2025	21.27 34.96% Unlock
2026	7.43 65.07% Unlock
2027	2.76 62.91% Unlock

Pluristem Therapeutics Inc....

Current Pluristem Therapeutics Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Alliance Global Partners	Locked ➜ Locked	Locked	Jun 02 2025

Analyst Rating	Date
Locked Alliance Global Partners: Locked ➜ Locked	Jun 02 2025

Discover more stocks with a high price target

TUI 63.33%

Alibaba Group Holding Ltd 39.18%

NIO ADR 36.92%

BioNTech SE - ADR 32.72%

MongoDB 29.30%

Adidas 27.47%

Tencent Holdings Ltd. 25.42%

Deutsche Telekom 25.28%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now